An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma
An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma
The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90089, United States
Hartford, Connecticut 06105, United States
Albuquerque, New Mexico 87131, United States
Stony Brook, New York 11794, United States
Bondy, 93143, France
Clichy, 92118, France
Paris, 75015, France
Berlin, 13353, Germany
Hanover, 30625, Germany
Mannheim, 68167, Germany
Barcelona, 08036, Spain